Orbia F&EM Communications
World’s Most Widely Used Medical Propellant Brand Celebrates Its 30-Year Anniversary
BOSTON, June 18, 2025—Orbia Advance Corporation S.A.B. de C.V. (BMV: ORBIA*) Fluor & Energy Materials marked the 30th anniversary of its leading medical propellant brand, Zephex®, with an event at its Rocksavage plant in Runcorn, United Kingdom. Attended by senior representatives from the pharmaceutical sector and U.K. Parliament, the celebration reflected the company’s legacy and looked ahead to its role in supporting a low-carbon future.
Over the past 30 years, Zephex® propellants have been used in more than three billion pressurized metered dose inhalers (pMDIs), helping treat 100 million asthma and COPD patients each year—approximately two-thirds of the global pMDI market.
At the event, Orbia reaffirmed its commitment to ensuring continued supply of Zephex® 134a, the world’s most widely used medical propellant, while scaling up production of Zephex® 152a, a next-generation propellant with significantly lower global warming potential (GWP). This dual approach will support a smooth industry transition to high performance, sustainable propellants.
Markus Laubscher, Business Unit Head for Pharma at Orbia Fluor & Energy Materials, said, “This week, we were pleased to be able to celebrate three successful decades of supporting respiratory patients worldwide. Our mission of widening access to life-saving, sustainable medical propellants through increased supply at affordable costs, will continue to drive our innovation and investments in the Zephex® brand.”
Laubscher added, “Our customers have and will continue to play a central role in the ongoing transition to low-GWP medical propellants, and our event has been as much a celebration of their leadership and commitment over the past 30 years as it has been to celebrate the Zephex® brand. I look forward to the continued progress of our new Zephex® 152a plant ahead of its grand opening next year.”
Notable attendees and Orbia customers included Chris Hirst (CEO, Bespak), Alessandro Chiesi (Chairman, Chiesi Group), Claire Lund (VP Sustainability, GSK), Milton Boyer (CEO, Kindeva) and Dan Carden, U.K. Member of Parliament. Cipla also contributed virtually.
The event featured a panel discussion on the transition to low-GWP medical propellants, covering topics including emissions reduction, treatment access and regional economic benefits from the Rocksavage investment. Guests toured the plant, which will be the home of the new facility upon its completion in 2026.
The Zephex® brand was born in 1995 when Orbia and GSK partnered to produce a new propellant that addressed the issue of ozone layer depletion. Since then, the Zephex® brand has served pharmaceutical customers globally with excellent quality, technical support and security of supply.
Orbia’s multi-million pound investment in the new Rocksavage facility will expand production of Zephex® 152a, supporting broad industry adoption for use in PMDIs and helping reduce sector emissions. A small scale plant has supported development and regulatory approval for the past three years. The expansion is expected to secure long-term jobs in Runcorn and contribute to the local and national economy.
Low GWP products like Zephex® 152a directly deliver on the Kigali Amendment to the Montreal Protocol, which mandates an 80% reduction in hydro-fluorocarbon (HFC) use by 2050.
Learn more about the Zephex® brand at https://www.kouraglobal.com/applications/medical-propellants/.
About Orbia
Orbia is a company driven by a shared purpose: to advance life around the world. Orbia operates in the polymer Solutions (Vestolit and Alphagary), Building & Infrastructure (Wavin), Precision Agriculture (Netafim), Connectivity Solutions (Dura-Line) and Fluor & Energy Materials sectors. The five Orbia business groups have a collective focus on addressing food and water security, expanding information access and connectivity and advancing decarbonization and the energy transition with basic and advanced materials, specialty products and innovative solutions. Orbia has a global team of over 23,000 employees, commercial activities in more than 100 countries and operations in over 50, with a strong U.S. manufacturing presence and headquarters in Boston, Mexico City, Amsterdam and Tel Aviv. The company generated $7.5 billion in revenue in 2024.
About Orbia Fluor & Energy Materials
Orbia’s Fluor & Energy Materials business is a global leader in the development, manufacture and supply of fluoroproducts that play a fundamental role in enhancing everyday lives and shortening the path to a sustainable, circular economy. Backed by over 35 years of experience, Orbia F&EM products are used in a vast range of applications, including electric vehicles and energy storage, urban and rural infrastructure, indoor climate management, food and medicine refrigeration, and treating respiratory conditions through development of healthy and innovative low-GWP propellants for metered- dose inhalers. Orbia has 1,700 employees and eight manufacturing facilities worldwide, serving 60 countries through a global sales and distribution network.
Media Contact:
Becki-Morgan Phillips
Junior Account Manager, Democracy PR
becki@democracypr@orbia.com
Maria Cristina Venturoli
Director of Strategic Marketing,
Orbia Fluor & Energy Materials
mariacristina.venturoli@orbia.com
+39 (347) 267-9734
